Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$30.90
▲ $0.90 (+3.0%)
Market data updated: 09/17 07:10 PM
Fundamentals updated: 09/17/2026
News analyzed: 09/17/2026
Market Cap
$1.21B
Day Range
$30.11 - $31.65
52-Week Range
$3.59 - $37.48
Beta
—
Next Earnings
—
ANRO is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+704.2% (1Y)
Strengths: 8/26 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Leverage risk
Debt/equity: 0.11
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$27.95 vs. price $30.90 (-190.5%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
46
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $30.25
Evidence: Panic-selling score jumped from 1 to 36 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
43
Quality
55
Value
38
Momentum
29
Risk
46
Sentiment
92
Fundamental
50
Institutional
No data available
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Alto Neuroscience, Inc. has primarily focused on its financial and leadership updates. The company announced Nick Smith’s promotion to president and chief financial officer, signaling strategic shifts. Despite reporting widened quarterly losses of $27.64 million in Q2 2026, analysts maintained a bullish stance, citing progress in its clinical-stage pipeline for neuropsychiatric disorders like bipolar and major depressive disorders. Stock performance saw a 93.73% year-to-date gain amid speculation about valuation and pipeline expansion.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Alto Neuroscience, Inc.. News trend score: 92. Reason: 9 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
43
🎯 Conviction (vs. Emotion)
52
Psychology
49
Fundamentals
50
Technical
29
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+35%
Market Narrative
49
Fundamental Reality
52
Narrative Gap
-3
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for ANRO strongly suggests **euphoria**, with extreme outperformance (+41.4% above 200-day average) and near-perfect sentiment (98/100) fueling overconfidence. The disconnect between price momentum (+4.6%) and stagnant EPS growth (+0.1%) hints at speculative overreach, while FOMO (32) indicates some traders are chasing gains despite peers lagging. The key open question is whether this narrative gap (69 vs. 52) reflects overvaluation or a delayed fundamental catalyst. Anchoring near resistance may reinforce holding behavior, but the dominant euphoria risks a sharp reversion if momentum stalls.
Updated: 09/09/2026, 03:11 AM
What could change this?
👥 What the crowd believes
"Alto Neuroscience announced the promotion of Nick Smith to president and chief financial officer"
"HC Wainwright & Co. analyst raises price target from $50 to $55"
"reported a net loss of US$27.64 million and a basic loss per share of US$0.65"
"Alto Neuroscience stock looks expensive with 90-day return of 47.43%"
🧠 Market Brain events driving this
📈 8D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 32/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect deep philosophical and methodological divides among the historical investors. Walter Bagehot’s near-perfect score highlights its liquidity resilience, aligning with his focus on financial stability during crises, while the majority—including Graham, Lynch, and Smith—caution due to mixed fundamentals or overpriced growth. Meanwhile, Fisher’s zero score underscores a lack of qualitative depth, contrasting sharply with the quantitative skepticism of Marks, Nelson, and Housel, who flag volatility, valuation risks, or late-cycle warning signs. Even the efficient-market camp dismisses it as unconvincing, whereas Veblen and Mackay’s low scores suggest behavioral red flags, like speculative fervor or crowd psychology. The split between Bagehot’s defensive optimism and the rest’s guardedness reveals whether the stock’s liquidity or its speculative traits dominate the analysis.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 91
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 60
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 58
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 58
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 54
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 47
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 46
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 44
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 35
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 33
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 32
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 9 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-41.8%
ROA
-34.2%
ROIC
—
EPS
-$2.19
Cash
$176.48M
Total Debt
$16.76M
Current Ratio
15.69
Debt/Equity
0.11
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$30.90
Estimated Fair Value (DCF)
-$27.95
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-190.5%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-56.97M | $-52.27M |
| 2 | 8.1% | $-61.60M | $-51.85M |
| 3 | 6.3% | $-65.45M | $-50.54M |
| 4 | 4.4% | $-68.31M | $-48.40M |
| 5 | 2.5% | $-70.02M | $-45.51M |
Base FCF (last actual year)
$-51.79M
Terminal Value
$-1.10B
Present Value of Terminal Value
$-717.66M
Enterprise Value
$-966.22M
Net Debt
$-159.73M
Equity Value
$-806.49M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$5.24
Tangible Book Value per Share (Tangible NAV)
$5.24
Sentiment based on basic keywords (not AI) — 9 positive, 9 neutral, 2 negative out of the last 20 articles.
Yahoo · 9.9.2026
Business Wire · 9.9.2026
MT Newswires · 27.8.2026
Yahoo · 27.8.2026
Business Wire · 27.8.2026
Benzinga · 27.8.2026
Benzinga · 17.8.2026
Simply Wall St. · 16.8.2026
Yahoo · 16.8.2026
Simply Wall St. · 16.8.2026
Yahoo · 16.8.2026
Simply Wall St. · 16.8.2026
Yahoo · 16.8.2026
MT Newswires · 14.8.2026
MT Newswires · 13.8.2026
Benzinga · 13.8.2026
Benzinga · 13.8.2026
Business Wire · 12.8.2026
Yahoo · 12.8.2026
Benzinga · 12.8.2026
Alto Neuroscience, Inc. (ANRO) currently has a StockIQ AI score of 46/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ANRO currently scores 46/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ANRO's estimated fair value is -$27.95, which is 190.5% below the current price of $30.90. This is one valuation model among several signals in the fair-value category, not a price target.
ANRO's technical score is 29/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Debt/equity: 0.11; Current ratio: 15.69; Price is above the 200-day average.
Based on the real signals StockIQ computed: Estimated fair value: -$27.95 vs. price $30.90 (-190.5%); ATR: 6.4% of price; Calmar: 0.18 (3y annualized return 16.2% / max drawdown 91.7%).
StockIQ has no recorded dividend payment history for ANRO.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Miller Andrew Craig | Grant/Award from Employer | 27.5.2026 | 26,000 | +26,000 | — |
| Miller Andrew Craig | Grant/Award from Employer | 27.5.2026 | 26,000 | +26,000 | — |
| Etkin Amit | Gift | 14.5.2026 | 400,000 | -400,000 | — |
| Etkin Amit | Gift | 14.5.2026 | 833,949 | -400,000 | — |
| York Gwill | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Dreyfus Andrew | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Cox Christopher Nixon | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Manji Husseini | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Sanchez Ramiro | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Dreyfus Andrew | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Sanchez Ramiro | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Cox Christopher Nixon | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| York Gwill | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Manji Husseini | Grant/Award from Employer | 12.5.2026 | 10,958 | +10,958 | — |
| Smith Nicholas Conrad | Tax Withholding in Shares | 1.3.2026 | 2,806 | -2,806 | $19.69 |
| Etkin Amit | Tax Withholding in Shares | 1.3.2026 | 6,227 | -6,227 | $19.69 |
| Smith Nicholas Conrad | Tax Withholding in Shares | 1.3.2026 | 24,060 | -2,806 | $19.69 |
| Etkin Amit | Tax Withholding in Shares | 1.3.2026 | 1,233,949 | -6,227 | $19.69 |
| Etkin Amit | Grant/Award from Employer | 11.2.2026 | 306,000 | +306,000 | — |
| Hanley Jr. Michael Conick | Grant/Award from Employer | 11.2.2026 | 131,000 | +131,000 | — |
| Smith Nicholas Conrad | Grant/Award from Employer | 11.2.2026 | 200,000 | +200,000 | — |
| Savitz Adam | Grant/Award from Employer | 11.2.2026 | 124,000 | +124,000 | — |
| Hanley Jr. Michael Conick | Grant/Award from Employer | 11.2.2026 | 131,000 | +131,000 | — |
| Etkin Amit | Grant/Award from Employer | 11.2.2026 | 306,000 | +306,000 | — |
| Savitz Adam | Grant/Award from Employer | 11.2.2026 | 124,000 | +124,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,836,359 shares short as of 2026-08-31 · vs. 3,235,210 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
78.6% of trading volume this week was short selling, vs. 68.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology